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Models for predicting the effect of immunological recognition of the bridge group on the dose- 
response curves obtained with heterogeneous hapten enzyme immunoassays are presented. Ap- 
propriate theoretical treatment shows that the greater affinity of antibodies toward the enzyme- 
labeled species than for the unlabeled hapten analyte results in assays with limited detection 
capabilities. This problem is compounded when enzyme conjugates possessing multiple haptens 
are used. In equilibrium type competitive arrangements. the concentrations of binder and labeled 
hapten may be optimized to some extent to improve assay performance. However. the results 
presented show that only when assays are performed in a sequential binding mode using carefully 
controlled timing of reagent incubations can the detection capabilities of the assays be fully max- 
imized for analyte measurements. Unfortunately, it is also shown that such sequential binding 
approaches render the assays essentially nonselective. The elfect of decreasing the affinity of the 
binder to the enzyme-labeled hapten relative to the unlabeled analyte by using heterologous 
conjugates in equilibrium arrangements is shown to improve detection capabilities but also at 
the expense of reduced selectivity. Suggestions for reagent concentrations and conjugate substitution 
(degree of conjugation). which provide optimized dose-response curves at a given EDSo value, 
are also presented as are proposals for using different binders which do not exhibit bridging group 
recognition. ,F’ 1986 Academx Press. Inc. 
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The use of enzymes rather than radioiso- 
topes as labels in competitive binding assays 
has resulted in the development of a wide 
range of new enzyme immunoassay (EIA)3 
techniques for measurement of important 
biological molecules (I-3). While the use of 
enzymes may overcome some of the costs and 
hazards associated with conventional ra- 
dioimmunoassay (RIA) procedures, the de- 
tection capabilities of such methods can often 
be limited. In some cases the detection limits 
can be drastically affected by antibody rec- 
ognition of the bridging group which cova- 
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and CHE-8506695 from the National Science Foundation. 
’ Present Address: Dept. of Chemistry, University of 
Kentucky, Lexington. KY 40506. 
’ Abbreviations used: EIA. enzyme immunoassay: RIA. 
radioimmunoassay. 
lently links the hapten (ligand) to the enzyme 
label (4-9). Since this same link is usually uti- 
lized in the preparation of hapten protein im- 
munogens used to elicit antibody formation, 
the resulting antibodies typically have a much 
higher affinity toward the enzyme-labeled 
hapten than for unlabeled analyte. The pur- 
pose of this report is to theoretically (based on 
a mass-action model) predict the behavior of 
assays in which this dissimilarity in binding 
affinities exists and to examine how variation 
in reagent concentrations and actual meth- 
odology (equilibrium vs sequential binding) 
can affect the dose-response curves. An ap- 
proach for optimizing reagent concentrations 
in equilibrium methods is also presented. 
Bridging group recognition problems are 
also often observed in classical RIA proce- 
dures, particularly when there is no method 
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for directly radiolabeling the haptenic species 
(10-12). For example, in RIAs of steroids, 
hemisuccinate derivatives of the steroids are 
used to couple these molecules to radioiodin- 
ated tyrosine to form the labeled reagent. The 
same hemisuccinate derivatives are also used 
to prepare the immunogen needed for anti- 
body production, and in these reports it is 
clearly shown that the resulting antisera have 
a higher affinity for the hemisuccinate deriv- 
ative than for the unmodified steroid. Similar 
problems can occur in newer fluoroimmu- 
noassay methods where the fluorescent tag 
must be covalently linked to hapten to form 
the labeled reagent (7). However, the problem 
is magnified considerably in EIAs since the 
derivatized hapten is typically linked to the 
enzyme through a lysine residue. Thus, aside 
from the derivatized arm of the hapten (e.g., 
hemisuccinate) the bridging group also in- 
cludes this lysine residue of the protein. Since 
the original immunogen also possesses the 
same derivative-lysine link, antibodies are 
likely to have an even greater affinity for labels 
containing the exact same sequence of bonds 
(i.e., enzyme-hapten conjugates). In general. 
the smaller the hapten species, the greater the 
chances of significant bridging group recog- 
nition problems. 
creased. Thus, the statistical association con- 
stant between the binder and the labeled spe- 
cies is increased, which further enhances the 
effect of bridging group recognition on assay 
performance. 
Aside from the multiplicity issue, our theo- 
retical analysis is based on plotting dose-re- 
sponse curves as bound vs logarithm of analyte 
concentration. While this type of plotting of 
EIA results is very common, there is a lack of 
theoretical treatment of this case, particularly 
when associated with the effect of bridging 
group recognition and multiple substitution 
of the label on assay performance. Further- 
more, in this report there is a theoretical ap- 
proach to nonequilibrium curves obtained 
when sequential binding methodologies are 
employed. Such a theoretical treatment is 
unique in the case of unequal binding affinities 
and, in view of the suggested advantages of the 
sequential binding approach for overcoming 
bridging group recognition, may aid in opti- 
mizing this alternate method. 
Although theoretical treatments have al- 
ready been reported for the case where labeled 
and unlabeled ligands demonstrate different 
affinities for the binder in immunoassays ( 13- 
16), these results apply to techniques which 
employ monosubstituted labeled species, such 
as RIA and fluoroimmunoassay. However, it 
is very common that the enzyme conjugates 
used in hapten EIAs are multivalent, with 
more than one ligand attached per enzyme 
molecule. The number of hapten molecules 
per molecule of enzyme depends on the con- 
ditions of the coupling reaction, as well as on 
the nature of both the enzyme and the hapten, 
and may vary from 1: 1 to 30: 1 or more. In 
this case the effective concentration of the Ia- 
beled ligand (i.e., ligand molecules attached to 
sites on the enzyme that are stereochemically 
unrestricted to approach by the binder) is in- 
Researchers have already proposed practical 
approaches to solve the bridging recognition 
problem in EIAs (4-6,17,18). The most logical 
approach is to reduce the affinity (association) 
constant between the labeled species and the 
antibody binder. Typically this is done by us- 
ing a structurally different bridge for preparing 
the labeled species than was used in the orig- 
inal immunogen (5.6). Empirically, it has been 
shown that this heterologous approach can 
improve the assay response toward the analyte 
but often decrease the selectivity of the assay. 
We now demonstrate that this decrease in se- 
lectivity can be predicted based on appropriate 
theoretical treatment of the relative change in 
affinity between the antibody and the labeled 
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MODELS FOR HETEROGENEOUS 
ENZYME-LINKED ASSAYS 
Equilibriwl mode. The principle of single- 
incubation enzyme-linked assays (otherwise 
called equilibrium mode or simultaneous ad- 
dition assays) is based on the competition of 
the enzyme-hapten conjugate and the unla- 
beled hapten (sample or standard) for a fixed 
number of binding sites of the specific binder 
(19). The higher the unlabeled hapten con- 
centration in the sample, the less conjugate is 
bound to the binder. Another protocol in- 
volves a preincubation of the specific binder 
with unlabeled ligand (analyte) followed by 
addition of the enzyme conjugate in a se- 
quential binding technique (otherwise referred 
to as delayed addition, or nonequilibrium, or 
two-step assay) (20). In this case, the amount 
of bound enzyme conjugate is also inversely 
related to the quantity of analyte. The proto- 
cols for both of these assays usually involve 
some type of separation step after an appro- 
priate incubation time (heterogeneous assays). 
This is accomplished either by immobilizing 
the antibody to a solid support or by using 
immobilized second antibody which has high 
affinity for the hapten-specific antibody (2 1). 
Once the activity of the enzyme is determined 
in the solid phase, a dose-response curve is 
plotted from the data obtained with standards, 
and the concentration of the unknown is in- 
ferred from this curve. 
For the single-incubation enzyme immu- 
noassay technique, labeled and unlabeled 
haptens are mixed first. followed by addition 
of the antibody and subsequent incubation of 
the mixture until equilibrium is achieved. The 
equilibrium expressions for this approach can 
be formulated as 
P+Q = QP, K 
P* + Q = QP*. K* [II 
where P is the unlabeled hapten (standard or 
sample), P* is the enzyme-hapten conjugate, 
and Q is the antibody. K and K* are the as- 
sociation constants for the two reactions. The 
initial concentrations of P, P*, and Q will be 
symbolized by a, a*, and q, respectively. The 
antibody will be considered immobilized on 
a solid support such that no dissociation of 
the antibody from the support can take place. 
In this way the separation of the bound and 
free fractions is accomplished in a single step. 
This assumption will be made throughout our 
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theoretical treatment and will simplify the 
modeling efforts (do not need to consider sec- 
ond equilibrium binding process (22)). 
value is an upper limit for KS,,,. Due to steric 
hindrance or site-site interactions, k’,,, is likely 
to be much smaller. 
For the case of single-step assays, dose-re- 
sponse curves were simulated assuming a sin- 
gle-incubation equilibrium system which em- 
ploys a binder possessing univalent, indepen- 
dent, and equivalent binding sites (described 
in Appendix I). For EIAs, such assumptions 
are met if a divalent antibody can simulta- 
neously bind two different enzyme-ligand 
conjugates. It was also assumed that the en- 
zyme conjugate was purified so that it did not 
contain any unconjugated hapten, any un- 
conjugated enzyme, or any conjugated inac- 
tive enzyme. 
Equilibrium mode: Efect of conjugute sub- 
stitution. To demonstrate the effect of the 
multivalency of the conjugate in the assay, the 
following model was used. The conjugate, EP,, 
was assumed to have an effective conjugation 
ratio (number of ligand molecules attached per 
enzyme molecule that can be bound by the 
binder) of 12. Further, the binder can associate 
with any of the n ligands that are conjugated 
to the same enzyme, but once the binder binds 
one of these ligands the other ligands become 
stereochemically restricted to such a binding 
and do not participate in any other equilibria. 
The last assumption is more likely true only 
when the binder is immobilized on solid sup- 
port. Finally, the multivalent conjugate will 
be considered as having independent ligand 
molecules, each one having the same micro- 
scopic association constant (for definition. see 
Ref. (23)) K*, for the binder. These assump- 
tions result in the reaction scheme 
Sequential binding mode. Sequential bind- 
ing assays have been customarily utilized to 
develop assays with steeper dose-response 
curves when compared to equilibrium tech- 
niques (20). Mathematical analysis of the ki- 
netics of this system has demonstrated the po- 
tential increase in the steepness of the curves 
inherent in this approach (24). Rodbard et al. 
(24) treated the case where the kinetics of the 
binding reactions for the labeled and unlabeled 
ligand are identical. However, this is not nor- 
mally the case when there is bridging group 
recognition involved and theoretical treatment 
of this situation has been mentioned (24) but 
never fully evaluated. 
The sequential binding assay involves a 
preincubation step of the unlabeled ligand with 
the binder, 
P+QLzQP. K=k,lkm,, 
followed by a second incubation after the la- 
beled ligand has been added to the reaction 
mixture. During the second incubation both 
the equilibrium equations 
P + Q k: QP, K = k,lkm, 
k2 
P* + Q c> QP*, K* = k2/kp2 
hold: the various parameters of this system are 
as defined before for the equilibrium system. 
k, and k2 are the association rate constants, 
and k-, and kp2 are the dissociation rate con- 
stants of the two reactions. 
P+Q = QP, K 
EP, + Q + QEP,, A;,,, = nK* [II] 
where Q, P, QP, K, and K* are as defined for 
Scheme [I], and Kstit is the association constant 
of this multivalent conjugate with the binder. 
Because the binder may bind to any of the n 
available ligands on the conjugate, it is statis- 
tically n times as probable for the binder to 
associate with the conjugate, K,,,, = nK*. This 
The theoretical simulation of this principle 
is based on a kinetic model similar to that sug- 
gested by Rodbard et al. (24) where the first 
incubation is long enough to allow equilibrium 
to be reached, while during the second incu- 
bation 
4QPl ~ = -kp,[QPl + k,Pl[Ql dt 
d[QP*l 
~ = -kp,[QP*] + kz[P*][Q]. At [2] U‘ 
[II 
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The model calculates the parameters [PI, [QP], 
and [Q] for the first incubation which serve as 
initial values for the set of Eqs. [l] and [2] (see 
Appendix II). 
For both assay modes (equilibrium and se- 
quential binding), in order to have a more 
general treatment, unitless parameters were 
used for the simulations. This was accom- 
plished by multiplying the various parameters 
with the association equilibrium constant, K, 
of the binder for the unlabeled analyte (e.g., 
dose-response curves of Kbound vs log Kp were 
generated instead of bound vs logp curves) or 
dividing by the amount of labeled ligand, p* 
(e.g.. dose-response curves of bound/a* vs log 
Kp were used) as described in the appendixes. 
These approaches allow a more direct com- 
parison of assay performances under various 
conditions. 
All data were obtained using programs 
written in Commodore BASIC and run on a 
Commodore CBM Model 8032 desk top 
computer. 
RESUL.TS AND DISCUSSION 
Several parameters have been used to define 
the “sensitivity” of immunoassay systems and 
this often results in misunderstandings within 
the competitive binding assay literature (25- 
27) and in different conditions for optimized 
assays (19). To avoid such a confusion, the 
term sensitivity will not be used in the follow- 
ing discussion. Instead, to evaluate and com- 
pare the performance of each assay modeled. 
three different parameters will be used as in- 
dicated in Fig. 1: (a) the maximum response, 
Kbo (i.e.. the response at zero dose normalized 
with respect to K), (b) the KEDso value (i.e., 
the effective dose that produces 50% of the 
maximum response, EDZo, again normalized 
with respect to K). and (c) the steepness of the 
dose-response curve. The steepness of the 
dose-response curve is defined as the maxi- 
mum value of its slope (maximum value of 
d(K[QP*])/d(log Kp)). This occurs at the in- 
flection point of the dose-response curve. The 
relative term &o/p* and the relative steepness 
10: 103 ’ 
KP 
KEDi, 
IO” 10 ’ 
FIG. 1. Family of equilibrium dose-response curves for 
Kmd (K[QP*]) as a function of the logarithm of nor- 
malized ligand concentration (Kp). The curves were gen- 
erated with K*/K ratios of 0.1, 1. 10. and 100. Both pa- 
rameters. Kq and Kp*. were fixed at 50 for all curves. The 
definitions of the various response parameters (Kb,. 
KED,o, and steepness) are also shown. 
(maximum value of d([QP*]/p*)/d(log Kp)) 
are also used to evaluate the response char- 
acteristics of the assays. The Kbo and KEDSD 
as well as the steepness and relative steepness 
are calculated as shown in Appendix III. The 
ED50 value does not necessarily correspond to 
the inflection point of the dose-response 
curve. Nevertheless, it is customary to use 
ED50 values rather than inflection point values 
to evaluate dose-response curves. 
According to these parameters, a limit on 
the detectability of the tracer will control the 
minimum affordable Kb,, value. The KEDSO 
value along with the steepness of the dose- 
response curve will then determine the re- 
sponse properties of the assay. In practice, 
random errors associated with measurement 
of low levels of bound enzyme-labeled species, 
pipetting errors, phase separation errors, etc., 
will statistically determine the detection ca- 
pabilities of the assays (9,27-29). Such statis- 
tical constraints can be evaluated if the re- 
sponse can be fitted to a four-parameter logistic 
model as suggested by Dudley ef al. (30). 
However, this approach cannot be used to 
predict the absolute effect of reagent concen- 
trations on the characteristics of the dose-re- 
sponse curves. Halfman and Schneider (28,29) 
have suggested optimization methods which 
include such statistical constraints (based on 
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a mass-action model) but their approach is re- 
stricted to the simple case of k’* = k’, which 
is even further simplified by assuming that the 
binder and the analyte are present in the assay 
system at concentrations greater than 1 /K and 
that p* > q. The more general approach of 
Yanagishita and Rodbard (3 1) is restricted to 
the case of equal affinity of the labeled and 
unlabeled ligand toward the binder. Conse- 
quently, statistical restrictions are not consid- 
ered here because for our model there is no 
simple analytical solution for the variance on 
the dose-response curve. However, in order 
to suggest reagent concentrations to be used 
when bridging group recognition occurs, as- 
sumptions regarding the minimum amount 
bound at zero dose, bo, are required, as is dis- 
cussed later. 
In equilibrium type methods, the difference 
in the affinity constants of the unlabeled and 
enzyme-labeled ligand for the binder drasti- 
cally affects the performance of the assays. This 
effect is summarized in Fig. 1 for values of 
binder and label concentrations in the range 
typically found in immunoassays (i.e., Kq 
= 50, Kp* = 50). In this case and in all sub- 
sequent studies the parameters Kg and Kp* 
refer to concentrations of the species in the 
assay tube. The same is true for the parameters 
Kbo, KEDso. steepness, and relative steepness. 
Curves generated with K*/K ratios of 10 and 
100 correspond to the case of relatively higher 
affinity constants for the conjugated than for 
the unlabeled ligand, a situation that is often 
encountered when there is bridging group rec- 
ognition. 
To better predict the properties of the equi- 
librium assay system for changes in the con- 
centration of the reagents, parametric studies 
were undertaken. The effects of varying the 
ratio p*/q on KEDSO and the steepness of the 
dose-response curve for given Kg (e.g., Kg 
= 50) are shown in Figs. 2 and 3. Figure 2 
indicates that for given Kg and Kp* values. 
the lower the K*/K, the lower the KEDSO value 
and, potentially, the lower the concentration 
of unlabeled ligand that can be detected. The 
actual detection limits, however, will be de- 
Kt? =50 
K*/K = 10 
I 
FIG. 2. Effect of changes in the p*/9 ratio (for kC9 = 50) 
on the log KEDSo value of equilibrium mode assays for 
various K*/K ratios. 
termined by several factors, including the de- 
tectability of the enzyme-labeled ligand. As can 
also be seen in Fig. 2, a minimum value of 
KEDSO is always observed at or near p*/q = 1. 
The increase in KEDso is marked as p*/q in- 
creases above this minimum, while the rate of 
increase is slower as p*/q decreases below the 
minimum. From Fig. 3 it is evident that there 
is an optimum relationship between K* and 
K for maximum relative steepness and for 
given Kg and Kp* values. Indeed, the relative 
steepness of the dose-response curve is re- 
duced drastically at very high or very low val- 
ues of K* relative to K. However, it can also 
be seen that bridging group recognition has 
less of an effect on the relative steepness of 
dose-response curves as the labeled ligand 
concentration approaches or exceeds the 
binding site concentration. 
The effect of combined changes in reagent 
concentration (Kg and Kp*) on the theoretical 
model for K*/K = 10 (bridging group recog- 
nition) is illustrated in Fig. 4. In most in- 
stances, the use of a lower concentration of 
binder and/or enzyme-labeled ligand will de- 
crease the KEDSD value. but at the same time 
decrease the steepness of the curve. The shape 
of the KEDso contour, at regions where p* > q 
and q > p*, is almost perpendicular to the Kp* 
and Kg axes. respectively. Thus, in order to 
improve the KEDso values when p* > q, a 
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Rc;. 3. Relationship between relative steepness ofdose- 
response curves and p*/q for Kq = 50 and various K*/h’ 
ratios (equilibrium mode). 
decrease in &I* is necessary while a change in 
Kq does little to reduce the KEDso value. 
Equivalently, when q > a*, a decrease in q, 
not changes in p*, is desired to improve the 
KEDso value. From this figure it can also be 
inferred that increasing the volume of the in- 
cubation mixture, which is equivalent to si- 
multaneously decreasing the concentrations of 
both q and p*. will improve the EDso but at 
the expense of the steepness of the dose-re- 
sponse curve. The same general conclusions 
can be drawn for the case where K*/K = 1 





FIG. 4. Contours of log KEDSo values (--; 1.S to 3.0 
within figure borders), steepness (-.-.-: -1 to -20 on 
right margin). and I& (---: I to 50 on top margin) eval- 
uated for K*/k’ = 10 and combined changes in Kq and 
Kp* (equilibrium mode). 
KP* 
FIG. 5. A family of contours for log KEDSo values (-: 
0.5 to 2.0 within figure borders), steepness (-. -. -; - 1 to 
~50 on right margin), and Kbho (---: 1 to 50 on top margin) 
evaluated for K*/li = I and combined changes in k;I and 
Kp* (equilibrium mode). 
group recognition there is almost a IO-fold 
improvement in KEDso values for the same 
Kp* and Kq values shown in Fig. 4. There is 
less of an effect on steepness and Kbo values. 
It should be noted that the regions examined 
on Figs. 4 and 5 are only those which would 
be useful for analytical purposes. 
An optimized assay protocol should employ 
an enzyme conjugate concentration, p*, so 
that its enzymatic activity can be easily mon- 
itored within a reasonably short measuring 
period, ‘Therefore, it is critical to employ an 
enzyme conjugate with high specific enzymatic 
activity for which sensitive detection tech- 
niques are available (i.e.. fluorescence). To 
demonstrate the utility of Figs. 4 and 5 in op- 
timizing assays, a hypothetical assay to mea- 
sure an analyte with a desired EDSo value of 
2 X 10e9 M is presented (if 100 ~1 of sample 
is used m a total assay volume of I ml. the 
corresponding ED50 for the sample will be 2 
X IO-” M). This assay assumes an antibody 
association constant toward the unlabeled li- 
gand of 5 X 10” M-’ (log KEDSO = 2) and a 
K*/K ratio of 10. A further assumption is that 
the concentration of the enzyme conjugate 
bound to the immobilized binder is high 
enough so that a sufficient absorbance signal 
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can be measured in the zero dose tube over a 
relative short period of time (e.g., 30 min). 
This b0 value is highly dependent on the mo- 
lecular weight and the specific activity of the 
enzyme label. For this example, a value of 2 
X 10-l ’ M was assumed as a minimum re- 
quirement for b0 (KbO = 1). In the case of al- 
kaline phosphatase, a label commonly used in 
enzyme immunoassays, this b. corresponds to 
an absorbance signal of 0.666 after 30 min 
incubation of the enzyme with the substrate 
(absorbance of sample minus the absorbance 
of the blank) assuming a molecular weight of 
100,000 (32) and a specific activity of 500 
units/mg for the enzyme (the product of the 
enzymatic reaction, p-nitrophenol, has an t405 
= 18.5 X lo3 M-’ cm-‘). Based on these as- 
sumptions, to optimize a dose-response curve 
to attain given ED5~ and required minimum 
bo values. the reagent p* and q concentrations 
can be easily found from Fig. 4 as the points 
on the log KEDSO contour that give values of 
Kbo 2 1. Since, in general, the desired two 
contours intersect at two points, two solutions 
are possible for each specific requirement for 
EDso and b. values. The intersect that gives 
p* > q is preferred since this conserves binder 
and at the same time yields dose-response 
curves with steepnesses imilar to the alternate 
solution, when the curves are plotted as bound 
labeled vs log dose. However, if the response 
curves are examined as bound labeled vs dose 
(rectangular coordinates), it is evident that the 
first set of reagent concentrations also results 
in curves with better initial slopes compared 
to the solution when p* < q, and therefore, 
lower concentrations of analyte may be deter- 
mined. 
the enzyme with the substrate(s), and thus, 
faster assays. For example, the dose-response 
curve that corresponds to Kq = 2 and Kp* 
= 10 will have a Kbo value of 1.98. The almost 
twice as high Kbo value (compared to the one 
obtained when Kq = 1.01 and Kp* = 10.4) 
allows the use of a 15-min, rather than a 30- 
min, incubation time period to generate the 
same absorbance signal of 0.666. However, if 
the b. value is too high, problems may occur 
because either the incubation time would need 
to be too short (n-reproducible results may thus 
be obtained) or the absorbance would be too 
high to be measured accurately. In compari- 
son, for the same p* and q, if no bridging group 
recognition were to occur (K*/K = 1 ), a lower 
ED5o value would be obtained without sub- 
stantial reduction of b. (see Fig. 5). 
The effect of the multivalency of the con- 
jugate on the relative steepness and ICEDSO 
values of dose-response curves is shown in Fig. 
6 for initial K*/K ratios of 10, 1, and 0.1. As 
noted earlier, increasing the number of ligands 
attached to the enzyme label effectively causes 
K* to become nK* = KS,,,, where n is the 
number of ligands attached to sites capable of 
being bound by the immobilized binder. This 
model applies when one assumes that once a 
ligand is bound by the binder, other ligands 
on the enzyme cannot also bind to the solid 
From Fig. 4, the concentrations of the re- 
agents that will yield the desired assay response 
curve using the minimum amount of binder 
possible are 2.08 X 10P” M for a* and 2.02 
X lo-” M for q. Note that the steepness (ab- 
solute) of the curves can be improved by in- 
creasingp* and/or q on the given ED50 contour 
above these two intersection points. Such 
steepness is associated with higher bo values 
which may permit a lower incubation time of 
FIG. 6. Effect of conjugate substitution on log KEDSo 
(curves A) and relative steepness (curves B) for three initial 
K*/K values: K*/K = 10 (-). K*/K = 1 (---). and K*/ 
K = 0. I (- * - * -). These curves were generated for equi- 
librium assays and Kq = ii>* = 50. 
phase. This assumption may or may not be bination of two or more of the heterology types 
true, but serves as a conservative model since, is also possible (5). In all their studies such 
if multiple ligands attached to the same en- approaches resulted in improved detection 
zyme could be bound simultaneously this limits of the assays but at the expense of re- 
would increase K,,,, enormously (up to lo4 duced selectivity. 
times, Ref. (33)) and make bridging group This technique of lowering the binding af- 
recognition problems even worse. It is evident finity between the enzyme-labeled species and 
from Fig, 6 that at least in the case of an en- the binder has been modeled for the case of 
zyme conjugate that possesses a chemical Kq = Kp* = 50 and for K/K, = 100, where K, 
bridge recognizable by the binder (K*/K > 1), is the association constant of the binder with 
the use of a multivalent conjugate will worsen the interferent (Fig. 7). A heterologous assay 
the detection capabilities of the assay. This will reduce K* without affecting the K and K,. 
theoretical finding is in agreement with ex- As shown. a reduction in the K* will improve 
perimental data ( 11,34). the detection capabilities toward the analyte 
From the above discussions, whenever K* as reflected by the KEDso values but at the 
> K, detection capabilities of the immunoas- same time, the selectivity (ID,,/ED,,: ID50 
says, in particular EIAs, deteriorate. Several equals the effective dose of the interferent that 
techniques have been used in practice to over- produces 50% of the maximum response) de- 
come this bridging group recognition problem. teriorates substantially (i.e., increased cross- 
For example, Van Weemen and Schuurs (4) reactivity). 
first realized the importance of heterology in A second approach for improving enzyme- 
their EIA for estrogens. Improved detection linked competitive binding assays has recently 
limits were obtained when the estrogen deriv- been suggested by this research team (17,18). 
atives employed for the preparation of the im- This approach involves the use of endogenous 
munogen and the enzyme conjugate were binding proteins rather than antibodies. These 
structurally related but different than the an- binding proteins are either specific globular 
alyte. By employing such a technique, the af- protein molecules with binding sites for a par- 
finity constant between the antibody and en- ticular ligand (e.g., serve to transport ligands 
zyme-labeled hapten is reduced without any within the body) or they may be certain en- 
change in the affinity between the binder and 
the unlabeled hapten. Thus, the unlabeled 
hapten has a better chance to compete with 
the conjugate for the binding sites of the an- 
120 300 
Kq =SO 




may become greater interferents in the assay. 
Indeed. Meyerhoff and Rechnitz (35.36) used 60 t 
cyclic GMP-enzyme conjugate and anti-cyclic 
AMP antibody to assay lower levels of cyclic 
“. 
AMP. This approach, however, resulted in re- P 
40 
duced selectivity over cyclic GMP. 
I 
Similarly, Van Weemen and Schuurs (5.6) 
investigated in detail the properties of heter- 
ologous assays. Besides hapten heterology, they 
studied the effect of changing the nature of the 
bridging group used in the preparation of the FIG. 7. Predicted KEDSo values (for analyte) and inter- 
enzyme-hapten conjugate (bridge heterology) 
ferent selectivity, IDSO/EDSO, in heterologous equilibrium 
and altering the site of hapten attachment to 
asays. Curves were generated assuming different degrees 
of heterology (K*/K ratio) and K/K, = 100 (Kq and Kp* 
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the enzyme (site heterology). Finally, a com- were fixed at 50). 
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zymes which possess allosteric ligand binding 
sites. Since the binder production need not be 
elicited by immunological procedures, there 
should be a naturally similar or higher affinity 
for the unlabeled than for the enzyme-labeled 
ligands (i.e., K*/K 5 1). As shown in Figs. 2, 
and 3 this situation gives rise to improved 
steepness and lower KEDso values. Such assays 
involving the use of appropriate binding pro- 
teins (immobilized on a solid phase support) 
in conjunction with a ligand-enzyme conju- 
gate have been developed for the detection 
of folate, vitamin B,?, and thyroxine (17,18). 
Naturally, such binding protein systems can 
be utilized only if they bind the analyte and 
the enzyme-labeled ligand with the high affin- 
ity necessary to detect low levels of analyte. 
Further, the selectivity obtained with such 
systems is controlled by the natural affinities 
of the binding protein toward the analyte and 
the respective interferents. 
A third approach to solve the bridging group 
recognition problem is to perform assays using 
a sequential binding technique. Such a tech- 
nique is dependent on kinetics rather than 
thermodynamics and is controlled by two sets 
of association and dissociation rate constants 
(see above model). 
A collection of values of association rate 
constants (37) for polyclonal antibodies with 
various radiolabeled haptens indicated rela- 
tively small differences. Values fell roughly in 
the IO-fold range of IO’ to IO* M- ’ SK’ (10’ 
M-’ so’ is the proposed diffusion controlled 
limit for this rate constant if the electrostatic 
repulsions between the hapten and the anti- 
body are taken into account (38)) while the 
dissociation rate constants varied in a lOOO- 
fold range. Smith and Skubitz (39) observed 
that the dissociation rate constants corre- 
sponding to the kinetics of the hapten with its 
respective hapten-specific antibody were lower 
than those corresponding to the same antibody 
with a hapten similar in structure but different 
than the one used to induce the antibody pro- 
duction. For example, rabbit digitoxin specific 
antibody had association rate constants of 1.4 
[3H]digitoxin, [3H]digoxin, and [“Hlouabain, 
respectively. On the other hand, the respective 
dissociation rate constants were 2.3 X 10m4, 
1.2 X 10e3, and 1.4 X lo-’ ss’. 
Generally, in sequential binding methods 
the first incubation is carried to equilibrium. 
Dose-response curves for this case are shown 
in Fig. 8 where the second incubation time is 
varied for fixed P/k and k-z/ii-, ratios. This 
variation is equivalent to variation in k-,1? 
values. The unitless parameter k- ,fz is used so 
that either differences in the second incubation 
time or differences in the dissociation rates of 
the unlabeled species can be assessed. As ex- 
pected, an increase in the second incubation 
time will result in dose-response curves that 
will eventually approach those obtained using 
an equilibrium type of assay. A value of kPlfZ 
= 0.1 is long enough for the label to nearly 
saturate available binding sites, but short 
enough so that significant reequilibration does 
not occur. This value will be used to generate 
all subsequent sequential binding assay data. 
The dose-response curves presented in Fig. 
9 were simulated using the parameters given 
in Table 1. Curves A,, AZ, and A3 were gen- 
erated using a P/K ratio of 10 and various 
LZ/kP, values. Similarly, curves B, , B?, and 
FIG. 8. Dose-response curves of a sequential binding 
assay for K*/K = 10 and given Kq and Kp*. The first 
incubation time was considered long enough to allow 
equilibrium while the second one was varied as indicated 
by the k-,t, parameter. An equilibrium assay curve was 
X lo’, 1.1 X lo’, and 1.3 X 10’ M-’ SC’ with generated usmg same parameters 
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FIG. 9. Sequential binding dose-response curves with 
K*/K and k2/k-, ratios as shown in Table I (fixed K9 
and A$* values at 50 and fixed second incubation time tL 
so that km,rz = 0.1). Labels A. B. and C refer to decreasing 
ratios of K*/K ( IO. I. 0.1). Numerals I through 3 represent 
the ratios X-Jk-, ( IO. I, 0. I, respectively). Cases AE . BE, 
and Cc. denote the corresponding equilibrium mode assays. 
B3 correspond to a K*/K value of 1, and curves 
C, , Cl, and C3 to a K*/K ratio of 0.1. In all 
cases it can be seen that the lower the km7/Li 
ratio, the shallower the curve and the lower 
the I& value. Further, the same trend is ev- 
ident when the K*/K ratio is lowered for a 
given kP2/kPl ratio. In addition, in the case of 
low K*/K (e.g., equal to 0.1 and k-2/k-, equal 
to 10) there was almost no advantage to se- 
quential binding mode over the equilibrium 
mode assays. 
An obvious disadvantage of this type of as- 
say protocol is that it involves a second in- 
cubation period which must be accurately 
controlled, thus increasing the time and dif- 
ficulty of the assay. Further, sequential binding 
type assays suffer a dramatic deterioration in 
their selectivity characteristics. For example, 
ED5” values of dose-response curves for the 
analyte and the ratio IDSo/EDSo for the inter- 
ferent are shown in Table 2 along with the 
parameters used to generate these curves. In 
Table 2 it is assumed that all differences in the 
affinity constants come from differences in the 
dissociation rate constants while the associa- 
tion rate constants remain unaltered. Based 
on known data (37,39) this is a reasonable as- 
sumption although it may not be valid in every 
case. The ED50 values for the analyte and the 
interferent indicate that in all three cases of 
Table 2 there is very limited selectivity (IDso 
values very close to the corresponding ED5o 
values:) of the assays. This theoretical finding 
has also been observed experimentally and was 
empirically explained by a “first come, first 
served” mechanism (40,4 1). Thus, unless it is 
desired to measure a whole class of compounds 
this mode of assay should be avoided. 
In summary. several conclusions can be 
drawn from the models presented here. For 
hapten EIAs in which the antibody exhibits 
bridging group recognition toward the en- 
zyme-labeled species, equilibrium type assays 
using analyte-enzyme conjugates with the 
same bridge as the immunogen will result in 
assays with limited detection capabilities, as 
defined by high EDso values and a lower steep- 
ness for the dose-response curves. In such 
cases, theory predicts that assay performance 
can be optimized to lower EDso values by 
varying the concentrations of binder and/or 
labeled ligand; however, this will reduce the 
steepness of the dose-response curve and. 
concomitantly. the precision of the method. 
Further. for given p* or q concentrations, 
steeper dose-response curves with lower ED5,, 
TABLE I 
PARAMETERS USED TO MODEL SEQUENTIAL BINIXNG 














P/K k-,/k-, X-z/k, 
IO IO 100 
IO I IO 
IO 0.1 I 
10 -a 
1 IO IO 
I 1 I 
I 0.1 0.1 
I - - 
0.1 10 I 
0.1 I 0.1 
0.1 0. I 0.01 
0.1 - 
a Rate constants not considered in equilibrium mode 
assays. 
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TABLE 2 



















values are obtained at p* N 9 (Figs. 2, 4, 5). 
In addition, the models presented suggest the 
use of conjugates with low hapten to enzyme 
ratio to avoid compounding the bridging 
group recognition problem. Equilibrium as- 
says utilizing heterologous conjugates (i.e., dif- 
ferent bridging group) may improve the per- 
formance of assays, but if the degree of het- 
erology is too excessive, assays with highly 
reduced selectivity will result. Performing se- 
quential binding type assays will, generally, 
increase the steepness and lower the ED50 
value of the dose-response curve but with a 
concomitant severe loss of assay selectivity. 
The concept of using endogenous hapten se- 
lective binding proteins rather than antibodies 
appears to offer a promising new approach 
since bridging group recognition is completely 
circumvented. However, such an approach is 
limited to systems for which there exists a 
suitable binding protein which will have a high 
enough affinity toward the analyte and en- 
zyme-labeled conjugate so that competitive 
binding assays with detection capabilities 
comparable to traditional immunoassays (e.g., 
RIAs) will result. 
Finally, while this study was undertaken to 
help explain and predict observations in hap- 
ten EIA systems, the models and data pre- 
sented here should help workers developing 
other types of immunoassays (e.g., fluoroim- 
munoassays and RIAs) to fully optimize the 
performance of their tests. 
APPENDIX I 
Mass Action Model of Heterogeneous 
Enzyme-Linked Assays 
To predict the effect of the difference be- 
tween K and K* on heterogeneous enzyme- 
linked competitive binding assays, dose-re- 
sponse curves were simulated assuming a 
single-incubation equilibrium system which 
employs a binder possessing univalent, inde- 
pendent, and equivalent binding sites and a 
univalent conjugate. These assumptions lead 
to the mass action model 
PSQ = QP, K 
P* + Q = QP*, K* [II 
where P is the unlabeled ligand, P* is the li- 
gand-enzyme conjugate, and Q is the specific 
binder. K and K* are the association constants 
for the two reactions. The initial concentra- 
tions of P, P*, and Q are symbolized by p, p*, 
and q, respectively. 
For simplification purposes, the incubation 
time will be considered long enough to reach 
equilibrium. Then, the following mass action 
equations can be written: 
[QPI 
K = MQI 
[QP*l 
K* = W*I[QI 
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P = PI + IQPI (31 
q = [Ql + [Qpl + [QP*l 141 
p* = [P*J + [QP*]. 151 
Equations (I] and (21 are solved for [QPJ 
and [QP*], respectively, taking into account 
the values of [P] and [P*] from (31 and (51. 
[Qp] = Kp[Q1 
1 + HQI [61 
[Qp*l = 
K*p*[Ql 
1 + K*(Q] 
171 
Then, by substitution into (41 
Y = IQ1 + 
KP[QI k’*p*[Ql 
1 + K[QJ + 1 + K*[Q] 
181 
or equivalently (normalized with respect to K) 
Kq = K/Q] + - 
KPK[QI 
1 + K[Ql 
+ (K*IK)Kp*K[QI 
1 + (K*/K)K[Q] ’ 
Given Kp, Kp*, Kg, and K*/K this equation 
can be solved for K[Q] by the secant numerical 
approximation method (42). Once K[Q] is 
known. K[QP*] can be calculated from the 
normalized (with respect to K) version of Eq. 
(71: 
(K*IK)Kp*K IQ1 
k'[QP*l = , + (K*/K)K[Q] ’ 
APPENDIX II 
Mass Action Model for the Sequential 
Binding Assay 
The sequential binding assay involves two 
incubation steps. First, the unlabeled ligand is 
incubated with the binder for a period of time 
which may or may not be enough to allow 
complete equilibrium: 
P+Qk2QP, K=k,/k-,. 
This preincubation step is described by the 
following set of equations: 
4QPl -- = -lie,[QP] + k,(P][QJ 
dt 
P = [PI + [QPI 
4 = LQI + IQPI. 
The labeled ligand is then added to the re- 
action mixture followed by a second incuba- 
tion: 
P + Q A; QP, K = k,/k-, 
xz 
P* + Q kT2 QP*, K* = k2/kpz. 
The parameters of this incubation step are de- 
scribed by the equations 
d[QPl 
dt 
- -k-m,[QPl + ~,F’l[Ql 
d[QP*l = -L[QP*] + &[P*J[Q] 
dt 
P = PI + [QPI 
Y = [Ql + IQPI + [QP*l 
p” = [P*] + [QP*]. 
Although analytical solutions ofthis system 
are available for the case where k, = k2 and 
km, = k-:! (43,44), the system gets quite com- 
plicated in the genera1 case of k, # k2 and k-, 
# km2. Therefore, a numerical solution is nec- 
essary. Because of its simplicity, the rectan- 
gular rule for numerical integration was em- 
ployed to solve the differential equations of 
this model (although better but more complex 
methods do exist, e.g., Runge-Kutta integra- 
tion). The two differential equations can then 
be rewritien as 
A[QPl = AW~JQPI + W’I[Ql) 
A[QP*] = At(-kml[QP*] + kl[P*][QJ) 
or 
K[QPln -- K[QPl,-I 
= -km,AtK[QP],-, + k-,AtK(P],-,K(Q]n-r 
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k’[QP*l n - K[QP*l np I
= -(k-?/k~,)k-,AtK[QP*].~, 
+ (k-z/k~,)li-,At(K*/K)KIP*].-,KIQ],~, . 
In the case when the first incubation is long 
enough and equilibrium is reached, the equa- 
tion 
[Qpl 
K = Pl[Ql 
holds and can be rewritten as 
K= [Qpl 
(9 - [QPIU - [Qpl) ’ 
This relationship yields a quadratic equa- 
tion which is used to calculate K[QP]: 
WIQPI)’ - (1 + ka + kHK[QPl) 
+ KqKp = 0. 
After K[QP] is estimated, the parameters 
K[P] and K[Q] are extracted from 
K[P] = Kp - K[QP] 
K[Q] = Kq - K[QP]. 
Thus, the model will calculate the param- 
eters K[P], K[QP], and K[Q] for the first in- 
cubation, which will serve as initial values for 
the parameters of the second incubation. 
The final values of the parameters are es- 
timated from the second incubation employ- 
ing an iteration step of li-, At, = 1 X lo-’ to 
ensure accuracy (i.e., if a klt2 value of 0.1 is 
used, a total of I X lo4 iterations will be un- 
dertaken) and successive iterations controlled 
by the equations 
K[QPln = KIQPln-I - ~-,&K[QPI,-I 
+ ~-,&fWln-~K[Qln~~ 
K[QP*l n 
=K[QP*],-, - (k~z/k~,)k-,At2K[QP*].-, 
+ (k-2/k-,)k~,At2(K*/K)K[P*]nlk’[Q]n~, 
KPI, = KP - K[QPln 
KIP*],I = Kp* ~ K[QP*],, 
KIQln = Kq - K[QP], ~ K[QP*].. 
For every one of these iteration steps the 
parameters K[QP]. K[P], and K[Q] will be es- 
timated. 
This numerical integration procedure was 
verified for the limiting case of li, = k2 and 
h--, = li-2 by comparison to the integration 
method described by Rodbard et al. (24) and 
the analytical solution of DeLean and Rod- 
bard (44). 
APPENDIX III 
KbO, KEDsO, Steepness, and Relative 
Steepness of Dose-Response Curves 
The Kb,, value is calculated from the de- 
scribed models by setting Kp = 0. To evaluate 
the KEDSO for the equilibrium model, the 
value of Kbo/2 is calculated first. Then, the 
KED50 is estimated numerically by the internal 
halving method as the value of Kp that cor- 
responds to a K[QP*] value of Kbo/2. The 
KEDSD in the case of sequential binding assays 
is determined graphically from the corre- 
sponding dose-response curves. 
The steepness of a dose-response curve is 
defined as its maximum slope. This is equiv- 
alent to the maximum of the derivative: 
d(KIQP*l) 
d(log Kp) . 
By taking the derivative of Eq. [6] 
4K[QP*l) = KK*p* 4Ql 
4og KP) (1 + K*[Q])’ d(log Kp) . 
The derivative of Eq. [8] with respect to log 
Kp yields 
4Ql = _ Kp[QlUoge 10) 
4w R-9 (1 + KIQIV ’ 
where A is given by the expression 
Kv K*v* 
A=l+ - 
(1 + K[Q1J2 + (1 + K-*[Q])‘. 
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Thus, the normalized equation (with respect 




(1 + W*IfW[Ql)*( 1 + MQIM ’ 
where K[Q] is calculated as described in Ap- 
pendix I. The maximum of this function, i.e., 
the steepness of the dose-response curve, is 
calculated numerically by the golden section 
method (42). 
The relative steepness is defined as the 
maximum of the derivative: 
cl([QP*l/~*) 
dlog 0) . 




(1 + (K*/K)K[Q])‘( I + K[Q])A ’ 
which can be evaluated by the golden section 
method as above. 
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